Mometasone furoate nasal spray for the treatment of asthma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Mometasone furoate nasal spray for the treatment of asthma. / Meteran, Howraman; Backer, Vibeke.

I: Expert Opinion on Investigational Drugs, Bind 25, Nr. 8, 2016, s. 999-1004.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Meteran, H & Backer, V 2016, 'Mometasone furoate nasal spray for the treatment of asthma', Expert Opinion on Investigational Drugs, bind 25, nr. 8, s. 999-1004. https://doi.org/10.1080/13543784.2016.1192124

APA

Meteran, H., & Backer, V. (2016). Mometasone furoate nasal spray for the treatment of asthma. Expert Opinion on Investigational Drugs, 25(8), 999-1004. https://doi.org/10.1080/13543784.2016.1192124

Vancouver

Meteran H, Backer V. Mometasone furoate nasal spray for the treatment of asthma. Expert Opinion on Investigational Drugs. 2016;25(8):999-1004. https://doi.org/10.1080/13543784.2016.1192124

Author

Meteran, Howraman ; Backer, Vibeke. / Mometasone furoate nasal spray for the treatment of asthma. I: Expert Opinion on Investigational Drugs. 2016 ; Bind 25, Nr. 8. s. 999-1004.

Bibtex

@article{ce8bd15c574c4cab9a9ee2a02f871817,
title = "Mometasone furoate nasal spray for the treatment of asthma",
abstract = "INTRODUCTION: Asthma is a common respiratory disease characterized by airway inflammation, bronchoconstriction and airway hyperresponsiveness and symptoms such as coughing, wheezing, shortness of breath and chest tightness. Allergic rhinitis is a common comorbidity in asthma and glucocorticoids are the key stone in the treatment of both diseases. Mometasone furoate is a potent synthetic steroid with a very high receptor affinity and a low bioavailability and shown to be superior compared to other inhaled corticosteroids. It is not clear whether the use of mometasone furoate nasal spray (MFNS) is associated with an improvement in asthma control.AREAS COVERED: This current paper reviews the current knowledge on the effect of mometasone furoate nasal spray in the treatment of asthma and includes clinical trials in which both subjective and objective outcomes are assessed.EXPERT OPINION: To date, only few clinical studies have investigated the effect of nasal steroids in the treatment of asthma. The studies investigating the effect of MFNS report contradicting results, although the most well-designed study to answer this question finds no improvement in asthma control. Thus, it seems unlikely that asthma guidelines will be influenced by the current knowledge on the effect of MFNS in the treatment of asthma.",
keywords = "Administration, Intranasal, Anti-Allergic Agents, Asthma, Glucocorticoids, Humans, Mometasone Furoate, Nasal Sprays, Treatment Outcome, Journal Article, Review",
author = "Howraman Meteran and Vibeke Backer",
year = "2016",
doi = "10.1080/13543784.2016.1192124",
language = "English",
volume = "25",
pages = "999--1004",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor & Francis",
number = "8",

}

RIS

TY - JOUR

T1 - Mometasone furoate nasal spray for the treatment of asthma

AU - Meteran, Howraman

AU - Backer, Vibeke

PY - 2016

Y1 - 2016

N2 - INTRODUCTION: Asthma is a common respiratory disease characterized by airway inflammation, bronchoconstriction and airway hyperresponsiveness and symptoms such as coughing, wheezing, shortness of breath and chest tightness. Allergic rhinitis is a common comorbidity in asthma and glucocorticoids are the key stone in the treatment of both diseases. Mometasone furoate is a potent synthetic steroid with a very high receptor affinity and a low bioavailability and shown to be superior compared to other inhaled corticosteroids. It is not clear whether the use of mometasone furoate nasal spray (MFNS) is associated with an improvement in asthma control.AREAS COVERED: This current paper reviews the current knowledge on the effect of mometasone furoate nasal spray in the treatment of asthma and includes clinical trials in which both subjective and objective outcomes are assessed.EXPERT OPINION: To date, only few clinical studies have investigated the effect of nasal steroids in the treatment of asthma. The studies investigating the effect of MFNS report contradicting results, although the most well-designed study to answer this question finds no improvement in asthma control. Thus, it seems unlikely that asthma guidelines will be influenced by the current knowledge on the effect of MFNS in the treatment of asthma.

AB - INTRODUCTION: Asthma is a common respiratory disease characterized by airway inflammation, bronchoconstriction and airway hyperresponsiveness and symptoms such as coughing, wheezing, shortness of breath and chest tightness. Allergic rhinitis is a common comorbidity in asthma and glucocorticoids are the key stone in the treatment of both diseases. Mometasone furoate is a potent synthetic steroid with a very high receptor affinity and a low bioavailability and shown to be superior compared to other inhaled corticosteroids. It is not clear whether the use of mometasone furoate nasal spray (MFNS) is associated with an improvement in asthma control.AREAS COVERED: This current paper reviews the current knowledge on the effect of mometasone furoate nasal spray in the treatment of asthma and includes clinical trials in which both subjective and objective outcomes are assessed.EXPERT OPINION: To date, only few clinical studies have investigated the effect of nasal steroids in the treatment of asthma. The studies investigating the effect of MFNS report contradicting results, although the most well-designed study to answer this question finds no improvement in asthma control. Thus, it seems unlikely that asthma guidelines will be influenced by the current knowledge on the effect of MFNS in the treatment of asthma.

KW - Administration, Intranasal

KW - Anti-Allergic Agents

KW - Asthma

KW - Glucocorticoids

KW - Humans

KW - Mometasone Furoate

KW - Nasal Sprays

KW - Treatment Outcome

KW - Journal Article

KW - Review

U2 - 10.1080/13543784.2016.1192124

DO - 10.1080/13543784.2016.1192124

M3 - Journal article

C2 - 27218300

VL - 25

SP - 999

EP - 1004

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 8

ER -

ID: 176701870